|
|
|
|
Bermuda |
|
001-37418 |
|
98-1333697 | ||||||||||
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB, United Kingdom
(Address of principal executive offices) (Zip Code)
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||||||
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||||||
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||||||
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each Class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered | ||||||||||
Common Shares, par value $0.00001 per share |
|
AXGT |
|
The Nasdaq Stock Market LLC |
|
|
|
AXOVANT GENE THERAPIES LTD. |
|
||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Dated: | April 20, 2020 |
|
|
|
|
|||||||||||||||
|
|
|
By: | /s/ David Nassif |
|
|||||||||||||||
|
|
|
Name: | David Nassif |
|
|||||||||||||||
|
|
|
Title: |
Principal Financial Officer and Principal Accounting Officer
|
|